Blue Yonder and nConnect Group Successfully Implement WMS Solution for Team Global Express in New Zealand
MELBOURNE, Australia & SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Team Global Express, Australia and New Zealand’s leading multi-modal logistics…
News
BrainChip and Lorser Industries to Develop Neuromorphic Computing Systems for Software-Defined Radio Devices
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), a global leader…
Relay Robotics Introduces Relay2, The New High-Capacity Hotel Delivery Robot
Relay2 brings 2X larger payload, customized accessories, and upgraded cloud-based elevator integration, enabling hotel owner/operators…
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69…
Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care
NEW YORK–(BUSINESS WIRE)–Massive Bio, a globally recognized leader in the oncology space, has proudly announced…
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached After 33.6 Months of Follow Up with First-Line Use of RYBREVANT®▼ (amivantamab) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung…
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
– Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in…
Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice
CHICAGO–(BUSINESS WIRE)–#biomarker—Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology,…
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety…
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC)…
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data…
Janssen Presents First Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson &…
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily…
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues…
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated…
Mountain Valley Pipeline To Proceed
Enactment of Federal Legislation to Raise U.S. Debt Limit Ratifies and Expedites Approvals, Declares Project…
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–$S—Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Findings in over 3,000 subjects demonstrate highly sensitive and specific detection of multiple cancers at…
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant…
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19…